newwin
Luciann Nguyen
Settings
← Accounts
biotech

Jemincare

53
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Jemincare

New trial — Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

New trialNCT07242274
53/100
Opportunity
Commercial fit11/25
Clinical timing18/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value7/10
Urgency1/5

New phase 3 trial NCT07242274 posted by Jemincare: "Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC". New trial on a phase 3 not yet recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 291 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT07242274
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC
phase 3
mol. elig.